Intervention Protocol

Aspirin for primary prevention of coronary heart disease

  1. Peter PR Jackson1,*,
  2. Mohsen Aarabi2,
  3. Erica Wallis1

Editorial Group: Cochrane Heart Group

Published Online: 26 JAN 2004

DOI: 10.1002/14651858.CD004586

How to Cite

Jackson PPR, Aarabi M, Wallis E. Aspirin for primary prevention of coronary heart disease (Protocol). Cochrane Database of Systematic Reviews 2004, Issue 1. Art. No.: CD004586. DOI: 10.1002/14651858.CD004586.

Author Information

  1. 1

    Royal Hallamshire Hospital, Clinical Pharmacology and Therapeutics, Sheffield, South Yorkshire, UK

  2. 2

    c/o Cochrane Heart Group, Department of Epidemiology & Population, London, UK

*Peter PR Jackson, Clinical Pharmacology and Therapeutics, Royal Hallamshire Hospital, Division of Clinical Sciences (South), University of Sheffield, Room 119, Floor L, Glossop Road, Sheffield, South Yorkshire, S10 2JF, UK.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 26 JAN 2004




  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To determine the effects, both harmful and beneficial of aspirin in the primary prevention of coronary heart disease.

Primary questions
Does aspirin prevent fatal and non-fatal CHD in people without symptomatic vascular disease?
Does aspirin reduce all-cause and cardiovascular mortality?

Secondary questions
Are the effects of aspirin, be they harmful or beneficial, affected by underlying risk of CHD?
Do the major adverse effects of Aspirin ever outweigh its benefit and is this balance affected by underlying CHD risk?